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Altered T Cell Receptor Ligands Trigger
a Subset of Early T Cell Signals
Joshua D. Rabinowitz,* Craig Beeson,* activation, is sufficient to cause, at least in some cases,
interleukin-2 (IL-2) production and T cell proliferationChristoph Wu¨lfing,† Keri Tate,*
Paul M. Allen,‡ Mark M. Davis,† (Kaibuchi et al., 1985; Truneh et al., 1985; Desai et al.,
1990).and Harden M. McConnell*
*Department of Chemistry In addition to these reactions, ligand–TCR binding
also causes colocalization of the TCR and coreceptor†Howard Hughes Medical Institute
Stanford University CD4 at the T cell–APC interface (Kupfer et al., 1987). It
has recently been shown that binding of the coreceptorStanford, California 94305
‡Center for Immunology and Department of Pathology CD8 to class I MHC enhances the affinity of class I MHC
ligand–cytotoxic TCR interaction by reducing ligand dis-Washington University School of Medicine
St. Louis, Missouri 63110 sociation rate (Luescher et al., 1995). It is likely that CD4
similarly prolongs the duration of helper TCR ligation by
binding to class II MHC. In addition, CD4 may play a
role in intracellular signaling events. The cytoplasmicSummary
tail of CD4 (like thecytoplasmic tail of CD8) is associated
with the tyrosine kinase p53lck (Lck), and this associationTCR ligands are complexes of peptides and MHC pro-
contributes to antigen-specific signal transduction (Za-teins on the surfaces of APCs. Some of these ligands
moyska et al., 1989; Chalupny et al., 1991; Glaichenhauscause T cell proliferation (agonists), while others block
et al., 1991; Abraham et al., 1991; Straus and Weiss,it (antagonists). We compared the acid release, cal-
1992; Xu and Littman, 1993; Dı´ez-Orejas et al., 1995).cium flux, and proliferation response of helper T cells
Approximately 5-fold overexpression of CD4 that lacksto a variety of ligands. We found that all agonist ligands
a cytoplasmic tail and thus fails to bind Lck is requiredbut not most antagonist ligands trigger acid release,
to restore helper T cell function in CD4 knockout micea general indicator of early cellular activation. Only a
(Killeen and Littman, 1993).subset of ligands triggering acid release cause sus-
Variants of antigenic TCR ligands can easily be pro-tained calcium flux, and only a subset of these ligands
duced by mutating the peptide portion of the ligand.cause T cell proliferation. Antagonist ligands and anti-
Such altered ligands can produce a wide range of bio-CD4 antibodies both effectively block T cell prolifera-
logical effects (reviewed by Jameson and Bevan, 1995).tion. However, significantly greater antagonist ligand
These include production of an altered cytokine profileor antibody concentrations are required to block acid
(Evavold and Allen, 1991; Windhagen et al., 1995), targetrelease and initial calcium influx. These data demon-
cell lysis without cytokine production (Evavold et al.,strate a hierarchy of early T cell signaling steps and
1995), induction of clonal anergy (Sloan-Lancaster etshow that altered TCR ligands can initiate some steps
al., 1993), and antagonism of response to wild-type anti-while blocking the completion of others.
gen (De Magistris et al., 1992). In addition, some altered
ligands can block some aspects of T cell response, whileIntroduction
triggering others (Racioppi et al., 1993; Ruppert et al.,
1993). In this report, we will refer to ligands that cause TActivation of helper T lymphocytes is a critical step in
cell proliferation at low concentration as agonist ligands.both humoral and cell-mediated immune response.
Ligands that never cause T cell proliferation but canHelper T cell activation involves ligation of multiple re-
block proliferation response to agonist ligand will beceptors on the T cell surface. These include two pro-
referred to as antagonist ligands. Ligands with someteins, the ab T cell receptor (TCR) and the coreceptor
agonist and some antagonist properties will be referredCD4, which bind to complexes of antigenic peptides
to as partial agonist ligands. We should point out thatand class II major histocompatibility complex (MHC)
the use of these pharmacological terms to describe TCRproteins. The ab TCR binds to the region of the peptide–
ligands is not strictly accurate, as TCR activation is notMHC complex surrounding the antigenic peptide, while
adequately described by classical affinity models forCD4binds to a nonpolymorphic region of MHC. Peptide–
receptor activation (Matsui et al., 1994). However, weMHC complexes, as well as the ligands for many other
feel that these terms nevertheless provide a useful quali-T cell surface receptors, are membrane proteins on the
tative description of T cell responses to altered ligands.surfaces of antigen-presenting cells (APCs).
A particular difficulty in discussing TCR antagonistBinding of peptide–MHC (henceforth referred to as
ligands is that peptides can block T cell activation atligand or TCR ligand) to the TCR triggers a series of
two different steps. First, any peptide that binds to MHCintracellular biochemical reactions in the T cell. These
(regardless of its TCR contacts) can competitively inhibitreactions have been the subject of intense study (re-
the presentation of antigenic peptide (Ishioka et al.,viewed by Weiss and Littman, 1994). The first reactions,
1994). Second, peptides with the appropriate TCR con-occurring within seconds, include tyrosine phosphoryla-
tacts can form antagonist ligands, which blockresponsetion of the TCR-associated CD3 and z proteins. These
to preformed agonist peptide–MHC complexes (De Ma-reactions result in recruitment of the tyrosine kinase
gistris et al., 1992). In this report, we will focus exclu-ZAP-70 to the TCR and activation of the phosphatidyl-
inositol pathway. This pathway, which triggers in- sively on this second type of antagonism, TCR antag-
onism.creased intracellular calcium and protein kinase C (PKC)
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TCR antagonism is of particular interest for several
reasons. Antagonist ligands may be involved in positive
selection of T cells in the thymus (Hogquist et al., 1994).
Mutant viral proteins containing peptides that form an-
tagonist ligands may allow viral escape from immune
response, resulting in persistent viral infection (Klener-
man et al., 1994; Bertoletti et al., 1994). Synthetic pep-
tides that form antagonist ligands may be used as drugs
for specific therapy of autoimmune disease (Kuchroo et
al., 1994; Franco et al., 1994). Moreover, TCR antagonist
ligands may act via a novel biochemical mechanism.
Three pieces of evidence strongly suggest that antag-
onist ligands are not classical competitive antagonists.
First, some antagonist ligands are active at very low
concentration (102 per APC), while the TCR is present at
high concentration (104 per T cell) (Harding and Unanue,
1990; De Motz et al., 1990; Christianick et al., 1991;
Klenerman et al., 1994; Bertoletti et al., 1994). Second,
the measured affinity of some antagonist ligands for the
TCR in solution is very low (approximately one order of
Figure 1. Hb and MCC Peptide Sequencesmagnitude weaker than antigenic ligand–TCR binding)
(Alam et al., 1996; Lyons et al., 1996). Thus, it would (A) Probable alignment of these peptides when presented on the
class II MHC protein I-Ek. The recent x-ray crytstal structure of thebe impossible for the low concentrations of antagonist
Hb peptide bound to I-Ek confirms that position 68 of Hb (isoleucine)ligands that are biologically active to block receptor
occupies the P1 pocket with position 76 (lysine) in the P9 pocket
occupation by antigenic ligand directly. Finally, antago- (Fremont et al., 1996).
nist ligands themselves cause partial CD3 z phosphory- (B) Name, sequence, and biological function of the altered peptides
lation (Sloan-Lancaster et al., 1994; Madrenas et al., studied in this report.
1995). These observations suggest that antagonist li-
gands trigger a series of biochemical events that some-
agonist ligands to a lower level on the signaling hierar-how render T cells less responsive to antigen.
chy. We conclude by discussing the implications ofTo investigate this mechanism in greater detail, we
these findings for models of TCR antagonism.
measured the ability of altered antigenic peptides pre-
sented on live APCs to trigger T cell acid release, calcium
Results
flux, and proliferation. Calcium flux and acid release are
complimentary assays that both measure T cell activa-
PL.17 T Cell Acid Release Response
tion within minutes of receptor ligation (Weiss et al., to Altered Hemoglobin Ligands
1984a, 1984b; Nag et al., 1992; McConnell et al., 1995).
The PL.17 T cell clone is triggered by the peptide corre-
Acid release (as measured on a microphysiometer) is a
sponding to residues 64–76 of the hemoglobin–bd pro-
general marker of cellular activity. Activation of most tein (the Hb peptide) bound to the MHC protein I-Ek. The
known signal transduction pathways can trigger in- alignment of the Hb peptide in the MHC-binding grove
creases in acid release (McConnell et al., 1992). Such of I-Ek, and the physiologic and biochemical responses
increases may reflect either increased production of of the T cell clone PL.17 to altered Hb ligands, have
acidic metabolites (e.g., lactate via glycolysis) or activa- been extensively evaluated in prior work (as summarized
tion of membrane proton transport proteins (e.g., the in Figure 1; Evavold et al., 1992, 1994, 1995; Sloan-
sodium–proton antiport) (McConnell et al., 1992; Wada Lancaster et al., 1993, 1994; Fremont et al., 1996). There-
et al., 1993). Intracellular calcium is a crucial early sec- fore, this system was ideal for comparing acid release
ond messenger, which is directly involved in T cell acti- to traditional measures of T cell activation.
vation (Kaibuchi et al., 1985; Truneh et al., 1985; Desai We measured the acid release response of a mixture
et al., 1990; Weiss et al., 1984a, 1984b). In contrast with of PL.17 T cells and APCs to previously studied single
acid release, calcium flux can be recorded in single cells amino acid mutants of the Hb peptide (Figure 1B). In-
as opposed to a bulk population of cells (Donnadieu et creased acid release is triggered by both Hb and partial
al., 1992, 1994; Ro¨tnes and Bogen, 1994; Torigoe et al., agonist 74A at low peptide concentration (Figure 2A).
1995; Agrawal and Linderman, 1995). None of the antagonist ligands trigger acid release at
In this report, we compare T cell acid release, calcium low concentration, but one (70M) markedly increased
flux, and proliferation in response to different combina- acid release at high concentration (Figure 2). This antag-
tions of agonist and antagonist ligands. We describe a onist has also been shown to cause transient spikes in
hierarchy of T cell responses in which acid release and intracellular calcium in single cell calcium flux assays
initial calcium flux are theeasiest to trigger and prolifera- (J. Sloan-Lancaster and P. M. A., unpublished data).
tion is the most difficult. The existence of such a hierar- Inactive ligand 72Q does not trigger acid release. Al-
chy indicates that early T cell signaling occurs in multiple though only one of the Hb antagonist ligands triggers
(although not necessarily sequential) steps. The effect significant acid release at the peptide concentrations
studied in this report, 70M and 70S both cause partialof antagonist ligands and anti-CD4 antibodies is to shift
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of altered Hb ligands to inhibit acid release triggered by
Hb. We first measured response to 1 mM Hb, added
either simultaneous with, or up to 2 hr following, addition
of 10 mM 70S or 72Q. Antagonist ligand 70S, but not
inactive ligand 72Q, caused a 20%–60% reduction in
PL.17 acid release if added either simultaneous with or
prior to Hb (three independent experiments, data not
shown). These results raised the intriguing possibility
that the antagonist ligand 70M might be able both to
trigger, and to block, PL.17 acid release. Indeed, while
70M alone causes some acid release, addition of 70M
followed by Hb results in reduced T cell acid release
compared with addition of Hb alone (Figure 2B). The
ability of antagonist ligands to block acid release is
consistent with previous results demonstrating that an-
tagonist ligands block other early T cell signals such as
T cell phosphatidylinositol hydrolysis and calcium flux
(Ruppert et al., 1993).
5C.C7 T Cell Response to Altered Moth Cytochrome
C Ligands Reveals More Stringent Requirements
for Proliferation than for Acid
Release or Calcium Flux
The 5C.C7 T cell line is derived from CD41 spleen cells
from a 5C.C7 TCR transgenic mouse (Fink et al., 1986;
Seder et al., 1992). It is triggered by the peptide corre-
sponding to residues 88–103 of the moth cytochrome
c protein (the MCC peptide) bound to the MHC protein
I-Ek. The effect of mutation of the MCC peptide on IL-3
production by a partially transformed 5C.C7 T cell clone
has been extensively evaluated (Reay et al., 1994). In
addition, the dissociation rate of altered MCC ligands
from the 2B4 TCR (which is similar in sequence and
ligand specificity to the 5C.C7 TCR) has been measured
in solution and correlates with T cell biological response
Figure 2. PL.17 Acid Release Response to Altered Hb Ligands
(Matsui et al., 1994; Lyons et al., 1996). Based on these
(A) Acid release response to agonist and antagonist ligands. The
studies, we chose to investigate 5C.C7 T cell acid re-rate of acid release of a mixture of PL.17 T cells and APCs was
lease and calcium response to three single amino acidmeasured before and after a 30 min exposure to the indicated pep-
tides. The increase in acid release triggered by these ligands is mutants of MCC with previously demonstrated biologi-
reported as a percentage of the increase triggered by 10 mM wild- cal activities (see Figure 1B; Reay et al., 1994; Lyons et
type Hb (30%). APCs were CHO cells transfected with I-Ek. A similar al., 1996; P. A. Reay and M. M. D., unpublished data).
response was obtained using CH27 cells as APCs in an independent
A variety of other peptides (99Q, 99E, 99A, 97I, 97Q, andexperiment.
triple mutant93E 99T 102A),which wereneither effective(B) Antagonist ligand 70M can both trigger and block PL.17 T cell
agonists nor antagonists of 5C.C7 IL-3 production inacid release. The rate of acid release of a mixture of PL.17 T cells
and CH27 APCs was measured every 90 s. Hb antagonist 70M (10 previous studies (Reay et al., 1994; P. A. Reay, unpub-
mM) was added during the interval indicated by the two shorter lished data), were included for comparison. The muta-
arrows, and unbound peptide was washed away. Wild-type Hb (1
tions studied are in TCR contact residues (see Figure
mM) was added at the time indicated by the long arrow for the
1A). All of these peptides form stable complexes withremainder of the experiment. Squares received 70M peptide and
I-Ek (Reay et al., 1994).Hb; circles did not receive 70M (open circles received Hb; closed
circles are negative control). Effect of another antagonist (73D) was Only one of these altered ligands, 102S, a conserva-
also measured in this experiment (data not shown). 73D alone re- tive single amino acid mutation (T→S) at a minor T cell
sulted in only a very slight increase in acid release, but 73D was as contact, results in 5C.C7 T cell proliferation (Figure 3A).
effective as 70M in blocking response to Hb.
Moreover, 102S is the only altered MCC ligand to trigger
marked acid release (Figure 3B). While the proliferation
dose response to partial agonist 102S and wild-typeCD3 z chain phosphorylation and can induce long-last-
MCC is very different, the acid release dose responseing T cell anergy (Sloan-Lancaster et al., 1994). There-
is almost identical (Figure 3). Moreover, no differencesfore, all antagonist ligands may trigger some early T cell
in acid release kinetics were noted between these twosignaling, but this signaling does not always cause acid
ligands (Figure 3C; for a detailed analysis of MCC re-release.
sponse kinetics see Beeson et al., 1996). Thus, it ap-To investigate the mechanism by which antagonist
ligands block T cell activation, we measured the ability pears that the requirements for triggering acid release
Immunity
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Figure 3. Comparison of 5C.C7 Proliferation, Acid Release, and Calcium Flux Response to Altered MCC Ligands
(A) MCC, but not partial agonist 102S, triggers proliferation at low concentration. Responses are reported as a percentage of maximum
[3H]thymidine incorporation in response to MCC (160 3 103 cpm). B10.BR mouse splenocytes were used as APCs. No increase in [3H]thymidine
incorporation above background (103 cpm) was found in response to MCC mutants 102G, 99R, 99E, 97I, or 97Q at concentrations up to 50
mM. Data are representative of five independent experiments.
(B) Both MCC and 102S trigger acid release at low concentration. The rate of acid release of a mixture of 5C.C7 T cells and APCs was
measured before and after 30 min exposure to the indicated peptides. 102S and MCC dose response curves were measured in separate
experiments, using response to 5 mM MCC (92% and 128%, respectively) as a standard for comparison. APCs were CHO cells transfected
with I-Ek. Similar acid release response to MCC and 102S was observed in greater than five independent experiments. Acid release response
to 102G, 99R, 99E, 97I, and 97Q was <10% of response to 1 mM MCC in all experiments using these peptides (all peptides were tested in at
least two experiments at concentrations up to 10 mM).
(C) Kinetics of acid release response to MCC and 102S are similar. At t 5 0 min, 1 mM of the indicated peptides was added to a mixture of
5C.C7 T cells and CH27 cells continuously for the duration of the experiment. Plotted is the rate of acid release as a percentage of the acid
release prior to the addition of peptide.
(D) Both MCC and 102S trigger increases in intracellular calcium at low concentration. Plotted is the percentage of 5C.C7 cells demonstrating
at least transient increases in intracellular calcium in response to APCs preincubated with MCC or altered MCC peptides. MCC and 102S
were diluted 1:1,000 into the inactive peptide 93E 99T 102A. 102G and 99R were not diluted. APCs were CHO cells transfected with I-Ek.
are more easily fulfilled than those for triggering prolifer- onds, while others remained at elevated calcium con-
centrations for minutes. Undiluted 102S resulted in aation. This is consistent with the ability of the Hb antago-
nist ligand M70 to trigger acid release but not prolifer- similar pattern of calcium response to 102S diluted
1:1,000 (data not shown), demonstrating that calciumation.
We also measured the single cell calcium flux re- flux, in contrast with acid release, depends only weakly
on peptide dose. Comparing the acid release, calciumsponse of 5C.C7 T cells to APCs preloaded with various
combinationsof altered MCC ligands. In all experiments, flux, and proliferative responses to 102S reveals that
transient calcium flux correlates with full acid releasethe biologically active peptides of interest were diluted
into the inactive peptide 93E 99T 102A to yield a total (Figure 3B) but only minimal proliferation (Figure 3A). In
contrast with the strong calcium response to agonist orpeptide concentration of 25 mM for APC loading. APCs
were washed to remove all free peptide prior to the partial agonist at 1:1,000 dilution, even the undiluted
antagonists 102G or 99R give no calcium flux in mostaddition of T cells. A 1:1,000 dilution of MCC or 102S
(an MCC or 102S concentration of 25 nM) results in cells. However, a transient calcium flux was observed
in >10% of 5C.C7 cells in response to 102G (Figure 3D).increased intracellular calcium in >90% of 5C.C7 T cells
(Figure 3D). However, MCC and 102S trigger qualita-
tively different patterns of calcium flux, with 102S re- Altered MCC Ligands Are More Efficient Antagonists
of 5C.C7 Proliferation than of Acidsulting in some transient calcium flux responses (data
not shown). These transient responses are character- Release or Calcium Flux
To determine which of the altered MCC ligands are TCRized by spikes to high intracellular calcium, followed
by a return to basal levels. Some cells demonstrating antagonists, we measured the ability of 102S, 102G,
99R, and 99E to block 5C.C7 proliferation triggered bytransient responses returned to basal levels within sec-
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a suboptimal concentration of MCC in a standard pre-
pulse antagonism assay (De Magistris et al., 1992). Not
surprisingly, increasing the concentration of 102S en-
hances proliferation (data not shown). In contrast, 102G
and 99R (but not 99E) are effective antagonists of T cell
proliferation when added in 10- to 50-fold excess of
MCC (Figure 4A).
To investigate how 99R and 102G block 5C.C7 prolif-
eration, we measured their ability to block 5C.C7 cal-
cium flux and acid release. As shown in circles in Figure
4B, addition of a 200-fold excess of 99R but not 99E
prior to addition of a suboptimal amount of MCC inhibits
5C.C7 acid release. This parallels inhibition of PL.17
response to Hb by addition of antagonist prior to ago-
nist. To determine whether the sequence of addition of
agonist and antagonist is important, we also added 99R
and 99E to cells that had already been triggered by
MCC. As shown in squares in Figure 4B, addition of an
antagonist peptide rapidly decreases 5C.C7 acid re-
lease. Thus, acid release depends on the relative
amounts of agonist and antagonist ligands present at
any given time, regardless of the order of addition. An-
other interesting aspect to this experiment is the rela-
tively small decrease caused by the 200-fold excess of
antagonist (10 mM). This excess of antagonist is suffi-
cient to block most 5C.C7 cell proliferation.
The effect of antagonists on calcium flux is consistent
with their effects on proliferation and acid release. As
shown in Figure 4C, the presence of even a 1,000-fold
excess of 102G or 99R relative to MCC has only a slight
effect on the percentage of cells giving a positive cal-
cium flux response. However, antagonist ligands are
capable of converting agonist-type calcium flux (full sig-
nals in all cells) to partial agonist type calcium flux (tran-
sient flux in some cells) (data not shown). To study fur-
ther the effect of antagonist on calcium flux, we reduced
the agonist ligand concentration 10-fold, while keeping
the antagonist ligand concentration the same. In this
case, both102G and 99R greatly reduce the frequency of
a positive calcium flux responses (Figure 4C). However,
even this large excess of antagonist (10,000-fold) does
not eliminate all calcium flux. Thus, it appears that
blocking calcium flux, like blocking acid release, is more
difficult than blocking proliferation. This result is in con-
trast with previous work demonstrating that the ability
to block calciumflux and proliferation are strongly corre-
lated (Ruppert et al., 1993). A likely explanation for this
discrepancy is that Ruppert et al. measure bulk, rather
than single cell, calcium flux.Figure 4. Antagonism of 5C.C7 T Cell Proliferation, Acid Release,
and Calcium Flux by Altered MCC Ligands
(A) 102G and 99R are effective antagonists of 5C.C7 proliferation. An Anti-CD4 Antibody Converts a Partial Agonist
5C.C7 T cells were incubated with the indicated peptides and APCs into an Antagonist, Despite Having a Minimal
prepulsed for 2 hr with 200 nM MCC. Proliferation was measured Effect on Acid Release and Calcium Flux
based on [3H]thymidine incorportation. Prepulsed APCs alone re-
Anti-CD4 antibodies can block helper T cell activationsulted in [3H]thymidine incorporation of 31 3 103 cpm. B10.BR
both in vitro and in vivo (Dialynas et al., 1983; Waldormouse splenocytes were used as APCs. Data are representative of
three independent experiments.
(B) 99R slightly inhibits 5C.C7 acid release when added either before
or after addition of MCC. Mixtures of 5C.C7 T cells and CHO cells acid release as a percentage of the rate prior to addition of peptide.
transfected with I-Ek were treated with two different peptides se- (C) A vast excess of 99R or 102G is required to block fully calcium
quentially as indicated by the arrows: 50 nM MCC followed by 10 flux response to MCC. 5C.C7 T cells were exposed to APCs preincu-
mM 99E (closed squares), 50 nM MCC followed by 10 mM 99R (open bated with wild-type MCC diluted either 1:1,000 or 1:10,000 into
squares), 10 mM 99E followed by 50 nM MCC (closed circles), 10 inactive peptide 93E 99T 102A or antagonist peptide 99R or 102G.
mM 99R followed by 50 nM MCC (open circles). Small diamonds are Plotted is the percentage of T cells showing increases in intracellular
the negative control and received no peptide. Plotted is the rate of calcium. APCs were CHO cells transfected with I-Ek.
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et al., 1985). We were interested in examining the effect
of the anti-CD4 antibody GK1.5 on T cell response to
different altered ligands. We first measured the ability
of anti-CD4 to block T cell proliferation. Figure 5 shows
the effect of varying concentrations of anti-CD4 on
5C.C7 proliferation. Plotted is dose response to wild-
type MCC (Figure 5A) or partial agonist 102S (Figure 5B)
in the presence of a fixed concentration of anti-CD4. A
low concentration of anti-CD4 (100 ng/mL) only slightly
inhibits proliferation in response to MCC but completely
eliminates the response to 102S. A 10-fold greater con-
centration of anti-CD4 blocks most but not all prolifera-
tion caused by MCC. GK1.5 Fab fragments produce
similar results (data not shown), demonstrating that the
effect of GK1.5 does not require cross-linking of CD4.
The ability of wild-type MCC but not partial agonist
102S to trigger proliferation in the presence of 100 ng/mL
anti-CD4 allows the measurement of 102S antagonist
function. As shown in Figure 5C, in the presence of anti-
CD4 and MCC, increasing concentrations of 102S block
5C.C7 proliferation. Because the APCs are prepulsed
with MCC, this blockade cannot be due to competition
for MHC binding and must result from a TCR specific
effect. Thus, anti-CD4 converts a partial agonist into a
TCR antagonist. A similar result has been previously
reported for CD81 T cells (Jameson et al., 1994).
To investigate the mechanism by which anti-CD4
blocks proliferation, we measured 5C.C7 acid release
and calcium flux in the presence of anti-CD4. In control
experiments, we found that in the absence of peptide,
anti-CD4 does not trigger acid release or calcium flux
(data not shown). Figure 6A shows that the acid release
response to 102S is not inhibited by a concentration of
anti-CD4 (100 ng/mL), which completely blocks prolifer-
ation response. Figure 6B summarizes the effect of anti-
CD4 on calcium flux response to MCC and 102S. While
1 mg/mL anti-CD4 does not completely block calcium
flux response to MCC or 102S, it tends to convert cal-
cium flux from an agonist to a partial agonist pattern
(data not shown).
Discussion
Defining a Hierarchy of Early T Cell Responses
Binding of the TCR and CD4 coreceptor protein to their
ligand, a complex of an antigenic peptide and a class
II MHC protein, activates helper T cells. Binding of an
altered ligand may cause partial T cell activation, block
T cell response to agonist ligand, or both. To investigate
the molecular mechanism of this differential T cell re-
Figure 5. Anti-CD4 Antibody GK1.5 Converts Partial Agonist 102Ssponse,we measured thepattern of early T cell signaling
into a T Cell Receptor Antagonist
by agonist, partial agonist, and antagonist ligands.
(A) 5C.C7 proliferation dose response to MCC in the presence ofT cell acid release was triggered by all agonist and
1 mg/mL (squares), 100 ng/mL (triangles), or no (circles) anti-CD4
partial agonist ligands but by only one of the five antago- antibody GK1.5. Responses are reported as a percentage of max-
nist ligands studied in this report (as summarized in imum [3H]thymidine incorporation in absence of anti-CD4 (164 3
Figure 7). Because acid release is triggered by most 103 cpm).
(B) Identical experiment to (A), using 102S in place of MCC.known signal transduction pathways (McConnell et al.,
(C) Antagonism of 5C.C7 T cell proliferation by 102S. 5C.C7 T cells1992), this suggests that many antagonist ligands do
were incubated with the indicated concentration of 102S, 100 ng/not trigger the production of large amounts of second
mL anti-CD4 antibody GK1.5, and APCs prepulsed for 2 hr with 200
messengers. However, one ligand that induces T cell nM MCC. Prepulsed APCs alone resulted in [3H]thymidine incorpora-
anergy did not trigger detectable acid release, demon- tion of 105 3 103 cpm. Assays were performed in triplicate. Plotted
strating that acid release cannot detect all T cell signal- is mean inhibition of [3H]thymidine incorporation 6 standard error.
B10.BR splenocytes were used as APCs in (A), (B), and (C).ing. Partial z phosphorylation is one event triggered by
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Figure 6. Anti-CD4 Antibody GK1.5 Only Slightly Alters 5C.C7 Acid
Release and Calcium Flux Responses
(A) GK1.5 does not affect either the magnitude or the kinetics of
acid release response to 1 mM 102S. Between t 5 0 min and t 5
30 min, either 1 mM 102S plus 100 ng/mL GK1.5 (squares) or 1 mM
102S alone (open circles) was added to a mixture of 5C.C7 T cells
and CH27 APCs. Closed circles are negative control (no peptide
added). Plotted is the rate of acid release as a percentage of the
rate prior to addition of peptide.
(B) Effect of GK1.5 on 5C.C7 calcium flux response. 5C.C7 T cells
Figure 7. Defining a Hierarchy of Steps in T Cell Activationwere exposed to APCs preincubated with either MCC or 102S (di-
luted 1:1,000 into inactive peptide 93E 99T 102A). The percentage (A) Summary of PL.17 T cell responses to altered Hb ligands. The
of T cells responding with increases in intracellular calcium was number of plus signs refers to the strength of a particular response.
measured in the presence of the indicated concentrations of anti- Minus signs indicate no response. z chain phosphorylation data are
CD4 antibody GK1.5. APCs were CHO cells transfected with I-Ek. taken from Evavold et al. (1994). In the case of z phosphorylation,
a single plus indicates predominant production of the p21 isoform,
while two plus signs indicate significant production of the p23
antagonist ligands that probably does not significantly isoform.
increase acid release. (B) Summary of 5C.C7 T cell responses to various combinations of
We found that one partial agonist ligand (102S), which altered MCC ligands.
(C) Schematic depicting proposed relationship between the com-is inefficient at causing proliferation, isnevertheless very
pleteness of a T cell response and the duration of TCR ligation byeffectiveat triggering acid release (Figure 3). This dichot-
peptide–MHC complex. Arrows depict where certain T cell re-omy demonstrates that there is not a one-to-one corre-
sponses might be located on such a plot, based on data in (A) and
spondence between a given level of acid release and (B). Phospho-z arrow placement is based on the ease of p21 z
later T cell responses. It is reminiscent of the ability chain phosphorylation. Phospho-z, z chain phosphorylation;H1, acid
of a different altered ligand to cause IL-4 but not IL-2 release; Ca21, calcium flux.
production (Evavold and Allen, 1991). We found that
ligands like 102S, which trigger acid release but not
proliferation, result in increased intracellular calcium in As a unit, and in combination with previous biochemi-
cal studies (Sloan-Lancaster et al., 1994; Madrenas etmost T cells. However, such ligands result in transient,
rather than sustained, increases in intracellular calcium al., 1995), these results suggest a hierarchy of measures
of T cell activation (Figure 7). At the bottom of the hierar-in many cases. Transient calcium fluxes triggered by
suboptimal TCR activation have been previously shown chy is initial CD3 z chain phosphorylation, as it is trig-
gered by ligands that failed to trigger any detectableto result in deficient IL-2 production (Goldsmith and
Weiss, 1988). response in this report (e.g., 70S, Figure 2). Just above
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z phosphorylation are initial calcium flux and acid re- signaling, it is not surprising that they tend to induce a
shift from a Th1 to a Th2 type cytokine profile (Stumbleslease, as these responses are triggered by a large num-
ber of different stimuli, many of which fail to yield T cell and Mason, 1995).
The ability of both antagonist ligands and anti-CD4proliferation.Of these two assays, calcium flux is slightly
more sensitive (e.g., 102G alone results in a very small to reduce the fraction of complete T cell signals sug-
gests that both act to shift T cell response to a lowerbut detectable calcium flux response but no detectable
increase in acid release). This is probably because a position on the hierarchy of signaling steps (Figure 7).
Based on this idea, we predict that it will be much easiersingle cell assay (calcium flux) is more effective than
an assay of bulk cellular response (acid release) for to block proliferation response to partial agonist than
to wild-type agonist, as partial agonist starts at a lowerdetecting a small response in a small fraction of cells.
Higher up are various types of sustained increases in position on the signaling hierarchy. Indeed, we have
found that an equimolar amount of 102G is sufficient tointracellular calcium, which can be subdivided based
on the precise temporal pattern of T cell response (C. W. block proliferation response to 102S (C. B., unpublished
data). Thus, one possible explanation for the ability ofet al., unpublished data). At the top of the hierarchy is
T cell proliferation, which requires nearly ideal activation some antagonists to block T cell response when the
agonist is in molar excess (Bertoletti et al., 1994; Klener-conditions. These conditions include the appropriate
APC and microenvironment (reviewed by Janeway and man et al., 1994) is that the agonists used in these re-
ports might be suboptimal.Bottomly, 1994), as well as the appropriate ligand. In
contrast with proliferation, and in accordance with their
lower location on the hierarchy, acid release and calcium Continuous Spectrum of T Cell Responses
Supports a Kinetic Discrimination Modelflux are relatively insensitive to APC type (Beeson et al.,
1996; Jenkins et al., 1987). of T Cell Activation and Antagonism
Two main hypotheses have been proposed to accountAn important question raised by this hierarchy is
whether the different responses are causally related for the difference in T cell response to agonist versus
antagonist ligands. These competing models can be(e.g., z phosphorylation causes calcium flux, which
causes acid release and proliferation). Acid release but labeled as a conformation model and a kinetic discrimi-
nation model. The conformation model claims that an-not calcium flux depends strongly on peptide dose.
Moreover, acid release increases steadily for at least tagonist ligand binding results in a conformation of the
TCR, which sends an incomplete or negative signal thatthe first 30 min of T cell stimulation, while intracellular
calcium frequently peaks rapidly and then declines can block response to antigen. Included in this idea are
models where the shape of the antagonist ligand resultswithin minutes of T cell activation. These disparities sug-
gest that acid release and calcium flux, despite occuring in failure to recruit CD4 (Yoon et al., 1994) or failure to
achieve appropriate TCR dimerization (Sette et al.,during a similar time frame and in response to similar
stimuli, are independent responses triggered by differ- 1994). In its simplest form, this model predicts a dichot-
omy between ligands that induce the correct conforma-ent signaling pathways. Thus, at least some of the re-
sponses on the signaling hierarchy appear not to be tion (agonists) and ligands that induce the other confor-
mation (antagonists). In thekinetic discrimination model,causally related and rather to be complementary mea-
sures of TCR signaling. a variant of kinetic proofreading (McKeithan, 1995), both
agonist and antagonist ligands bind the TCR in an identi-
cal manner. The only difference is that agonist ligands
Antagonist Ligands and Anti-CD4 Antibodies bind to the TCR for a longer duration than antagonist
Shift Agonist Ligands to a Lower Level ligands. In such a model, brief TCR occupation by an
on the Signaling Hierarchy antagonist ligand triggers incomplete signaling that can
The ability of antagonist ligands to block early T cell block response to agonist (Rabinowitz et al., 1996). This
signaling (Ruppert et al., 1993), but not always all cyto- model is supported by direct measurements of the dis-
kine production (Racioppi et al., 1993) raises the follow- sociation rate of mutant MCC ligands for the 2B4 TCR
ing dilemma: if early signaling is blocked, how can some (Matsui et al., 1994; Lyons et al., 1996) and by evidence
cytokine production persist? The analysis of early T cell that ligands causing partial T cell activation tend to have
signaling in this report (as summarized in Figure 7) pro- lower TCR affinities and faster dissociation rates than
vides a simple solution to this dilemma. We find that ligands triggering full T cell activation (Al-Ramadi et al.,
antagonist ligands have a dual affect on T cell signaling 1995; Alam et al., 1996; Margulies, 1996). It predicts that
when measured at the level of single cell calcium flux. the continuous range of dissociation rates of ligands
This effect is to reduce both the fraction of cells re- from the TCR will result in a continuous spectrum of T
sponding to agonist, and the fraction of these responses cell responses. The data in this report (as summarized
that are complete. Because a mixture of complete and in Figure 7) provide evidence for a continuous spectrum
incomplete signals is probably sufficient for production of T cell responses, suggesting that the kinetic discrimi-
of some but not all cytokines (Evavold and Allen, 1991; nation model is a likely possibility.
Racioppi et al., 1993; Windhagen et al., 1995), these The coreceptor CD4 contributes both to the stability of
results explain both the strong correlation between ligand–TCR interaction and (via Lck) to the intracellular
blockade of early signaling and blockade of prolifera- events required for complete T cell signaling. Therefore,
tion, and the ability to block selectively the production the kinetic discrimination model (aswell as some confor-
of a subset of cytokines. As anti-CD4 antibodies have mation models in which CD4 recruitment is crucial) pre-
dicts that reduction in CD4 expression will convert somea similar effect to antagonist ligands on early T cell
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agarose (Molecular Devices, Sunnyvale, California) at 378C. The aga-partial agonist ligands causing T cell proliferation into
rose cell mixture (10 mL) was immediately spotted onto the mem-ligands blocking proliferation. We tested this hypothesis
brane of a Cytosensor cell capsule (Molecular Devices, Sunnyvale,using anti-CD4 monoclonal antibodies to approximate
California). After 10 min, the cell capsule was assembled and loaded
a reduction in CD4 expression. As predicted, anti-CD4 in the microphysiometer chamber maintained at 378C. The chamber
converted a partial agonist ligand into an antagonist was perfused (50mL/min) with low buffer RPMI 1640 medium (Molec-
ular Devices, Sunnyvale, California) containing 1 mM sodium phos-ligand. Recent results have also shown that increasing
phate, 1 mg/mL endotoxin-free bovine serum albumin (Calbiochem,CD4 expression can convert an antagonist into an ago-
San Diego, California), and no bicarbonate (pH 7.4). The rate of acidnist, and, most interestingly, an inactive ligand into an
release was determinedwith 20 spotentiometric rate measurementsantagonist (Vidal et al., 1996). This final result is consis-
after a 58 s pump cycle and 10 s delay (total cycle time, 90 s).
tent with a kinetic discrimination model but not confor- Baseline acid release rates were between 60–100 mV s21.
mation models in which CD4 recruitment is crucial.
An unresolved question raised by the kinetic discrimi- Calcium Imaging
For calcium imaging 5CC7 T cells were loaded for 30 min at roomnation model is how a T cell integrates a mixture of
temperature with 2 mM Fura-2. CHO cells transfected with I-Ek werecomplete and incomplete receptor triggering to yield a
grown in 8-well coverslips (Nunc, Naperville, Illinois) and peptidefunctional response. While the data in this report do not
loaded with 25 mM peptide between 4–16 hr. After washing unbound
offer a full answer to this question, they demonstrate peptide away, Fura-2–loaded Tcells were added, on the microscope
that the T cell at least partially intergrates these different stage, onto a patch of confluent CHO cells to start the experiment.
receptor events early in the signaling pathway. The abil- Intracellular calcium in T cells was determined using C Imaging-
1280 System hardware and the Simca Quantitative Fluorescenceity of the T cell to discriminate accurately between a
Analysis Software Package (both from Compix, Incorporated, Im-large number of low affinity ligands (e.g., 99R or 102G)
aging Systems, Mars, Pennsylvania). The imaging system was cou-and a small number of moderate affinity ligands (e.g.,
pled to a Nikon Diaphot 300 inverted microscope, which was102S) at the stage of acid release or initial calcium flux
equipped with the epifluorescence attachment and a 75W Xenon
suggests that incomplete receptor activation can block arc lamp. Alternate excitation of Fura-2–loaded T cells at 340 and
one of the earliest steps in generation of a complete 380 nm was achieved using a Ludl high speed dual filter wheel (Ludl
Electronic Products, Hawthorne, New York) controlled by the Simcareceptor signal.The ability of antagonist ligand to rapidly
software. Images were collected with a CCD camera (Dage-MTIdecrease the acid release of a T cell already activated
CCD72) in combination with a SuperGenII intensifier (Dage-MTI,by agonist (Figure 4B) furthersupports this notion. These
Michigan City, Indiana) to amplify fluorescence. Analysis of intracel-
results are most easily explained by a model in which lular calcium was achieved with the Simca software package. Prior
all TCR ligands trigger both positive and negative sig- to T cell activation, emission intensity at 380 nm is greater than
nals, with different T cell responses requiring different emission intensity at 340 nm. A positive T cell calcium flux response
was defined as an increase in intracellular calcium sufficient toratios of the two. Identification of the molecular events
produce a decrease in emission at 380 nm to less than emission atinvolved in blockade of a positive T cell response by
340 nm for at least 20 s.incomplete receptor activation presents a challenge for
future investigation of TCR antagonism.
Cell Proliferation
Proliferation of 5C.C7 T cells was measured as the uptake of
Experimental Procedures [3H]thymidine. Rested T cells (3 3 104) and irradiated (3,000 rads)
B10.BR spleen cells (5 3 105) were incubated with serial dilutions
Peptides and Antibodies of peptides in a 96-well plate. We added 1 mCi [3H]thymidine at 48
Peptides were synthesized with standard FMOC chemistry, purified hr and cell DNA was harvested at 64 hr. Background radioactivity
by reverse phase high pressure liquid chromatography, and charac- was <1,000 cpm.
terized either by mass spectroscopy or amino acid content. Anti-
CD4 antibody GK1.5 (anti-L3T4) was purchased from Becton-Dick- Acknowledgments
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